{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T15:42:53Z","timestamp":1790091773951,"version":"4.0.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T00:00:00Z","timestamp":1701820800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T00:00:00Z","timestamp":1701820800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1184238"],"award-info":[{"award-number":["1184238"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["2014900"],"award-info":[{"award-number":["2014900"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["451092"],"award-info":[{"award-number":["451092"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001505","name":"Health Research Council of New Zealand","doi-asserted-by":"publisher","award":["20\/344"],"award-info":[{"award-number":["20\/344"]}],"id":[{"id":"10.13039\/501100001505","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Athlae Lyon\/Starship Foundation Trust","award":["ASF2144_WEBB"],"award-info":[{"award-number":["ASF2144_WEBB"]}]},{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","award":["CTGIIT21nov-0002"],"award-info":[{"award-number":["CTGIIT21nov-0002"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]},{"name":"United Kingdom National Institute for Health Research","award":["NIHR133719"],"award-info":[{"award-number":["NIHR133719"]}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MC_UU_00004\/07"],"award-info":[{"award-number":["MC_UU_00004\/07"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The <jats:italic>Staphylococcus aureus<\/jats:italic> Network Adaptive Platform (SNAP) trial is a multifactorial Bayesian adaptive platform trial that aims to improve the way that <jats:italic>S. aureus<\/jats:italic> bloodstream infection, a globally common and severe infectious disease, is treated. In a world first, the SNAP trial will simultaneously investigate the effects of multiple intervention modalities within multiple groups of participants with different forms of <jats:italic>S. aureus<\/jats:italic> bloodstream infection. Here, we formalise the trial structure, modelling approach, and decision rules that will be used for the SNAP trial. By summarising the statistical principles governing the design, our hope is that the SNAP trial will serve as an adaptable template that can be used to improve comparative effectiveness research efficiency in other disease areas.<\/jats:p><jats:p><jats:bold>Trial registration<\/jats:bold><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05137119\">NCT05137119<\/jats:ext-link>. Registered on 30 November 2021.<\/jats:p>","DOI":"10.1186\/s13063-023-07718-x","type":"journal-article","created":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T12:02:31Z","timestamp":1701864151000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["A blueprint for a multi-disease, multi-domain Bayesian adaptive platform trial incorporating adult and paediatric subgroups: the Staphylococcus aureus Network Adaptive Platform trial"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3643-923X","authenticated-orcid":false,"given":"Robert K.","family":"Mahar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"McGlothlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Dymock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd C.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger J.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Lumley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jocelyn","family":"Mora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin R.","family":"Saville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Snelling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven A.","family":"Webb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua S.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven Y.\u00a0C.","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie A.","family":"Marsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the SNAP Global Trial Steering Committee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asha","family":"Bowen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Daneman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Goodman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Heriot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd C.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Lye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Marsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"McGlothlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe","family":"McQuilten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jocelyn","family":"Mora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Morpeth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Paterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Owen","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Scarborough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiaan","family":"van Hal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevieve","family":"Walls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Webb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynda","family":"Whiteway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dafna","family":"Yahav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,6]]},"reference":[{"key":"7718_CR1","unstructured":"GBD 2019 Antimicrobial Resistance Collaborators. Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2022;400(10369):2221\u201348."},{"issue":"3","key":"7718_CR2","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1128\/CMR.00134-14","volume":"28","author":"SYC Tong","year":"2015","unstructured":"Tong SYC, Davis JS, Eichenberger E, Holland TL, Fowler VG. Staphylococcus aureus: epidemiology, pathophysiology, clinical manifestations, and management. Clin Microbiol Rev. 2015;28(3):603\u201361.","journal-title":"Clin Microbiol Rev."},{"issue":"11","key":"7718_CR3","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1093\/cid\/ciac476","volume":"75","author":"SYC Tong","year":"2022","unstructured":"Tong SYC, Mora J, Bowen AC, Cheng MP, Daneman N, Goodman AL, et al. The Staphylococcus aureus Network Adaptive Platform Trial Protocol: new tools for an old foe. Clin Infect Dis. 2022;75(11):2027\u201334.","journal-title":"Clin Infect Dis."},{"issue":"4","key":"7718_CR4","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.ijantimicag.2019.05.020","volume":"54","author":"A Henderson","year":"2019","unstructured":"Henderson A, Harris P, Hartel G, Paterson D, Turnidge J, Davis JS, et al. Benzylpenicillin versus flucloxacillin for penicillin-susceptible Staphylococcus aureus bloodstream infections from a large retrospective cohort study. Int J Antimicrob Agents. 2019;54(4):491\u20135.","journal-title":"Int J Antimicrob Agents."},{"key":"7718_CR5","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.ijantimicag.2018.02.013","volume":"52","author":"JS Davis","year":"2018","unstructured":"Davis JS, Turnidge J, Tong S. A large retrospective cohort study of cefazolin compared with flucloxacillin for methicillin-susceptible Staphylococcus aureus bacteraemia. Int J Antimicrob Agents. 2018;52(2):491\u20135.","journal-title":"Int J Antimicrob Agents."},{"issue":"7","key":"7718_CR6","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.cmi.2019.03.010","volume":"25","author":"S Weis","year":"2019","unstructured":"Weis S, Kesselmeier M, Davis JS, Morris AM, Lee S, Sherag A, et al. Cefazolin versus anti-staphylococcal penicillins for the treatment of patients with Staphylococcus aureus bacteremia: a systematic review and meta-analysis. Clin Microbiol Infect. 2019;25(7):818\u201327.","journal-title":"Clin Microbiol Infect."},{"key":"7718_CR7","doi-asserted-by":"crossref","unstructured":"Tong SYC, Lye DC, Yahav D, Sud A, Robinson JO, Nelson J, et al. Effect of vancomycin or daptomycin with vs without an antistaphylococcal \u03b2-lactam on mortality, bacteremia, relapse, or treatment failure in patients with MRSA bacteremia: a randomized clinical trial. JAMA. 2020;323(6):527\u201337.","DOI":"10.1001\/jama.2020.0103"},{"issue":"1","key":"7718_CR8","doi-asserted-by":"publisher","first-page":"dlac014","DOI":"10.1093\/jacamr\/dlac014","volume":"4","author":"AJ Campbell","year":"2022","unstructured":"Campbell AJ, Dotel R, Braddick M, Britton PN, Eisen DP, Francis JR, et al. Clindamycin adjunctive therapy for severe Staphylococcus aureus treatment evaluation (CASSETTE)\u2014an open-labelled pilot randomized controlled trial. JAC-Antimicrob Resist. 2022;4(1):dlac014.","journal-title":"JAC-Antimicrob Resist."},{"issue":"5","key":"7718_CR9","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1056\/NEJMoa1710926","volume":"380","author":"HK Li","year":"2019","unstructured":"Li HK, Rombach I, Zambellas R, Walker AS, McNally MA, Atkins BL, et al. Oral versus intravenous antibiotics for bone and joint infection. N Engl J Med. 2019;380(5):425\u201336.","journal-title":"N Engl J Med."},{"issue":"5","key":"7718_CR10","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1056\/NEJMoa1808312","volume":"380","author":"K Iversen","year":"2019","unstructured":"Iversen K, Ihlemann N, Gill SU, Madsen T, Elming H, Jensen KT, et al. Partial oral versus intravenous antibiotic treatment of endocarditis. New Engl J Med. 2019;380(5):415\u201324.","journal-title":"New Engl J Med."},{"key":"7718_CR11","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1056\/NEJMra1510062","volume":"377","author":"MD Woodcock","year":"2017","unstructured":"Woodcock MD, LaVange LM. Master protocols to study multiple therapies, multiple diseases, or both. New Engl J Med. 2017;377:62\u201370.","journal-title":"New Engl J Med."},{"issue":"16","key":"7718_CR12","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1001\/jama.2015.2316","volume":"313","author":"SM Berry","year":"2015","unstructured":"Berry SM, Connor JT, Lewis RJ. The platform trial: an efficient strategy for evaluating multiple treatments. JAMA. 2015;313(16):1619.","journal-title":"JAMA."},{"issue":"1","key":"7718_CR13","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1186\/s13063-019-3664-1","volume":"20","author":"JJH Park","year":"2019","unstructured":"Park JJH, Siden E, Zoratti MJ, Dron L, Harari O, Singer J, et al. Systematic review of basket trials, umbrella trials, and platform trials: a landscape analysis of master protocols. Trials. 2019;20(1):572.","journal-title":"Trials."},{"key":"7718_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jclinepi.2020.04.025","volume":"125","author":"JJH Park","year":"2020","unstructured":"Park JJH, Harari O, Dron L, Lester RT, Thorlund K, Mills EJ. An overview of platform trials with a checklist for clinical readers. J Clin Epidemiol. 2020;125:1\u20138.","journal-title":"J Clin Epidemiol."},{"key":"7718_CR15","doi-asserted-by":"crossref","unstructured":"Meyer EL, Mesenbrink P, Dunger-Baldauf C, F\u00fclle HJ, Glimm E, Li Y, et al. The evolution of master protocol clinical trial designs: a systematic literature review. Clin Ther. 2020;42(7):1330\u201360.","DOI":"10.1016\/j.clinthera.2020.05.010"},{"issue":"3","key":"7718_CR16","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1177\/1740774515626362","volume":"13","author":"BR Saville","year":"2016","unstructured":"Saville BR, Berry SM. Efficiencies of platform clinical trials: a vision of the future. Clin Trials. 2016;13(3):358\u201366.","journal-title":"Clin Trials."},{"key":"7718_CR17","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29\u2013. Identifier NCT05137119, Staphylococcus Aureus Network Adaptive Platform Trial (SNAP). 2021 Nov 30 [cited 2022 Apr 1]. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05137119."},{"issue":"19","key":"7718_CR18","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1001\/jama.2020.25007","volume":"325","author":"S Murthy","year":"2021","unstructured":"Murthy S, Fontela P, Berry S. Incorporating adult evidence into pediatric research and practice: Bayesian designs to expedite obtaining child-specific evidence. JAMA. 2021;325(19):1937.","journal-title":"JAMA."},{"key":"7718_CR19","first-page":"101","volume-title":"Bayesian Data Analysis","author":"A Gelman","year":"2014","unstructured":"Gelman A, Carlin JB, Stern HS, Dunson DB, Vehtari A, Rubin DB. Hierarchical models. In: Bayesian Data Analysis. 3rd ed. Boca Raton: Chapman and Hall\/CRC Press; 2014. p. 101\u201337.","edition":"3"},{"issue":"22","key":"7718_CR20","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1001\/jama.2018.17977","volume":"320","author":"AE McGlothlin","year":"2018","unstructured":"McGlothlin AE, Viele K. Bayesian hierarchical models. JAMA. 2018;320(22):2365\u20136.","journal-title":"JAMA."},{"issue":"5","key":"7718_CR21","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1177\/1740774513497539","volume":"10","author":"SM Berry","year":"2013","unstructured":"Berry SM, Broglio KR, Groshen S, Berry DA. Bayesian hierarchical modeling of patient subpopulations: efficient designs of phase II oncology clinical trials. Clin Trials. 2013;10(5):720\u201334.","journal-title":"Clin Trials."},{"key":"7718_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1201\/EBK1439825488","volume-title":"Bayesian Adaptive Methods for Clinical Trials","author":"SM Berry","year":"2010","unstructured":"Berry SM, Carlin BP, Lee JJ, M\u00fcller P. Bayesian adaptive methods for clinical trials. In: Bayesian Adaptive Methods for Clinical Trials. 1st ed. Boca Raton: Chapman and Hall\/CRC Press; 2010. p. 1\u201317.","edition":"1"},{"key":"7718_CR23","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1201\/EBK1439825488","volume-title":"Bayesian Adaptive Methods for Clinical Trials","author":"SM Berry","year":"2010","unstructured":"Berry SM, Carlin BP, Lee JJ, M\u00fcller P. Sequential stopping. In: Bayesian Adaptive Methods for Clinical Trials. 1st ed. Boca Raton: Chapman and Hall\/CRC Press; 2010. p. 150\u20131.","edition":"1"},{"key":"7718_CR24","unstructured":"Robertson DS, Lee KM, L\u00f3pez-Kolkovska BC, Villar SS. Response-adaptive randomization in clinical trials: from myths to practical considerations. arXiv:2005.00564v3 [statME]. 2021;1\u201360."},{"key":"7718_CR25","doi-asserted-by":"crossref","unstructured":"Villar SS, Robertson DS, Rosenberger WF. The temptation of overgeneralizing response-adaptive randomization. Clin Infect Dis. 2020;73(3):ciaa1027.","DOI":"10.1093\/cid\/ciaa1027"},{"key":"7718_CR26","doi-asserted-by":"crossref","unstructured":"Bofill\u00a0Roig M, Krotka P, Burman CF, Ekkehard G, Hees K, Jacko P, et\u00a0al. On model-based time trend adjustments in platform trials with non-concurrent controls. arXiv:2112.06574v1 [statME]. 2021;1\u201337.","DOI":"10.1186\/s12874-022-01683-w"},{"issue":"5","key":"7718_CR27","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1177\/17407745221112013","volume":"19","author":"BR Saville","year":"2022","unstructured":"Saville BR, Berry DA, Berry NS, Viele K, Berry SM. The Bayesian time machine: accounting for temporal drift in multi-arm platform trials. Clin Trials. 2022;19(5):490\u2013501.","journal-title":"Clin Trials."},{"key":"7718_CR28","first-page":"1","volume":"20","author":"B Carpenter","year":"2016","unstructured":"Carpenter B, Gelman A, Hoffman M, Lee D, Goodrich B, Betancourt M, et al. Stan: a probabilistic programming language. J Stat Softw. 2016;20:1\u201337.","journal-title":"J Stat Softw."},{"key":"7718_CR29","unstructured":"R Core Team. R: a language and environment for statistical computing. Vienna; 2023. https:\/\/www.R-project.org\/.\u00a0Accessed 27 Oct 2023."},{"key":"7718_CR30","first-page":"275","volume-title":"Bayesian Data Analysis","author":"A Gelman","year":"2014","unstructured":"Gelman A, Carlin JB, Stern HS, Dunson DB, Vehtari A, Rubin DB. Basics of Markov chain simulations. In: Bayesian Data Analysis. 3rd ed. Boca Raton: Chapman and Hall\/CRC Press; 2014. p. 275\u201392.","edition":"3"},{"key":"7718_CR31","doi-asserted-by":"publisher","first-page":"e000497","DOI":"10.1136\/bmjmed-2023-000497","volume":"2","author":"IC Marschner","year":"2023","unstructured":"Marschner IC, Jones M, Totterdell JA, Mahar RK, Snelling TL, Tong SY. Transparent reporting of adaptive clinical trials using concurrently randomised cohorts. BMJ Med. 2023;2:e000497.","journal-title":"BMJ Med."},{"key":"7718_CR32","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29\u2013. Identifier NCT04483960, Australasian COVID-19 Trial. 2020 Jul 23 [cited 2022 Apr 1]. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04483960."},{"key":"7718_CR33","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29\u2013. Identifier NCT02735707, Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia. 2016 Apr 3 [cited 2022 Apr 1]. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02735707."}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-023-07718-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-023-07718-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-023-07718-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T12:04:36Z","timestamp":1701864276000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-023-07718-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,6]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["7718"],"URL":"https:\/\/doi.org\/10.1186\/s13063-023-07718-x","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,6]]},"assertion":[{"value":"10 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The SNAP trial was initially approved by an Australian human research ethics committee (HREC Reference Number: HREC\/74098\/MH-2021). Ethical approval is sought from a properly constituted and accredited human research ethics committee (HREC) or institutional review board (IRB) for all trial sites. Where possible, a single lead committee will provide approval for all sites under its purview. Local site-specific approvals will also be sought where required by local regulations. Written informed consent is obtained from all participants or their surrogate decision makers prior to entry into the platform.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Anna McGlothlin is an employee of Berry Consultants LLC, in which capacity she is contracted as a consultant to numerous pharmaceutical and device companies on topics of statistical modelling and trial design, and reports grants and contracts unrelated to this work and consulting fees from Berry Consultants LLC. Todd C. Lee reports research salary support from Fonds de Recherche Quebec-Sante, operating funds for other studies including CATCO from the CIHR; and operating funds for other studies from the McGill Interdisciplinary Institute Infection and Immunity. Roger J. Lewis is an employee of Berry Consultants, LLC, a statistical consulting firm that specialises in the design of adaptive and platform clinical trials. Berry Consultants received compensation for work included in the content of the submission. Steven Y. C. Tong reports a contract as a paid consultant for advice on clinical trial design, and consulting fees from Roivant Sciences as a paid consultant for advice on clinical trial design. Steve A. Webb reports personal consulting fees from ClinicIQ pharma and Roche; an unpaid role as chair of Australian Clinical Trials Alliance; and stock and options with ClinicIQ. All other authors report no potential conflicts.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"795"}}